New drug duo aims to train immune system to fight blood cancer
NCT ID NCT05783596
Summary
This study is testing how well and how safely a combination of two immunotherapy drugs works for people with certain slow-growing lymphomas who have not yet received treatment. The drugs, glofitamab and obinutuzumab, are designed to help the body's own immune system find and attack cancer cells. About 47 participants will receive the treatment for about 9 months and be followed for up to 10 years to see how they respond.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Mount Sinai Medical Center
New York, New York, 10128, United States
Conditions
Explore the condition pages connected to this study.